On March 4, the US Food and Drug Administration (FDA) approved tislelizumab-jsgr in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

For more information, read the Beigene press release.

Posted on 3/12/25